Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications

Biological Psychiatry

Volumn 49, Issue 3, 2001, Pages 200-210

  Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AD; APP 670 671; Cholinesterase inhibitors; Human brain; Nicotinic agonists; Nicotinic receptor subtypes; PET ligands

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; MECAMYLAMINE; MESSENGER RNA; NERVE GROWTH FACTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; ONDANSETRON; RECEPTOR SUBTYPE; TACRINE;

ALZHEIMER DISEASE; AUTOPSY; BINDING AFFINITY; BINDING SITE; BRAIN TISSUE; COGNITION; DISEASE ASSOCIATION; DRUG MECHANISM; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; LIGAND BINDING; MEMORY; NEUROPROTECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION;

AGED; ALZHEIMER DISEASE; BRAIN; CHOLINERGIC AGENTS; HUMANS; RECEPTORS, NICOTINIC; TREATMENT OUTCOME;

EID: 0035251677     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01125-2     Document Type: Review

References (98)

1. Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres
2. 3H] acetylcholine receptor autoradiography
3. Nucleotide sequence of the human nicotinic acetylcholine receptor β2-subunit gene
4. Beta-amyloid peptides as direct cholinergic neuromodulators. A missing link?
5. Brain activation of young and old adults during implicit and explicit retrieval
6. Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease
7. Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192-IgG saporin lesions of the nucleus basalis magnocellularis
8. Evolution of neuronal changes in the course of Alzheimer's disease
9. Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7)
10. Heterogenity in dementia: Challenge and opportunities
11. CNS nicotinic receptors - Possible therapeutic target in neurodegenerative disorders
12. Age-related decrease in muscarinic cholinergic receptor binding in human brain measured with positron emission tomography (PET)
13. Dopamine receptor-mediated regulation of striatal cholinergic activity: Positron emission tomography studies with norchloro[18F]fluoroepibatidine
14. Smoking and dementia in male British doctors prospective study
15. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease
16. Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors
17. Molecular cloning of human nicotinic a3 subunit
18. Worldwide prevalence and incidence of dementia
19. Measurement of α4β2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT
20. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease
21. Decreased protein level of nicotinic receptor a7 subunit in the frontal cortex from schizophrenic brain
22. Influence of lipid peroxidaion on the nicotinic acetylcholine receptors in PC12 cells
23. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease
24. Amyloid, the presenilins and Alzheimer's disease
25. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord
26. Regional distribution of nicotinic receptor subunit mRNA in human brain: Comparison between Alzheimer and normal brain
27. Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease
28. Measurement of acetylcholinesterase by positron emission tomography in the brain of healthy controls and patients with Alzheimer's disease
29. Effects of acute subcutaneous nicotine on attention, information processing, and short-term memory in Alzheimer's disease
30. Presynaptic neuronal nicotinic receptors: Pharmacology, heterogeneity, and cellular mechanisms
31. Towards a structural basis for the function of nicotinic acetylcholine receptors and their cousins
32. Nicotinic receptor stimulation protect neurons against beta-amyloid toxicity
33. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease
34. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease
35. Decreased α7 nicotinic acetylcholine receptor protein levels in sporadic Alzheimers disease hippocampus
36. The role of nicotinic acetylcholine receptors in cognitive function
37. Nicotinic acetylcholine receptors in health and disease
38. 11C] nicotine binding assessed by PET a dual tracer model evaluated in the rhesus monkey brain
39. Allostrically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
40. Noncompetitive agonism at nicotine acetylcholine receptors: Functional significance for CNS signal transduction
41. Alpha 4 but not alpha 3 and alpha 7 nicotinic acetylcholine receptor subunits are lost in the temporal cortex in Alzheimer's disease
42. Neuronal nicotinic receptor deficits in Alzheimer patients with the swedish amyloid precursor 670/671 mutation
43. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by ± [3H]epibatidine
44. Alzheimer disease
45. Gene structures and transcriptional regulation of the neuronal nicotinic acetylcholine receptors
46. 11C) nicotine: Historical aspects
47. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid
48. PET quantification of specific binding of carbon-11-nicotine in human brain
49. Human cerebral acetylcholinesterase activity measured with positron emission tomography procedure, normal values and effect of age
50. Clinical aspects of nicotinic agents: Therapeutic application in central nervous system disorders
51. Nicotinic system involment in Alzheimer's disease and Parkinson's diseases. Implication for therapeutics
52. PET studies and cholinergic therapy in Alzheimer's disease
53. The effect of cholinesterase inhibitors studied with brain imaging
54. Noninvasive exploration of nicotinic acetylcholine receptors in vivo
55. Heterogenous cholinergic nicotinic receptors in the CNS
56. Responders and non-responders to tacrine, ondansetron and NGF treatment in Alzheimer patients as evaluated by positron emission tomography and APOE genotype
57. Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG and cognitive abilities
58. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography
59. Activity of acetylcholinesterase in CSF increases in Alzheimer patients after treatment with tacrine
60. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
61. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment
62. 11C-nicotine binding in normal and Alzheimer brains - In vivo assessment using positron emission tomography
63. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerance and pharmacology
64. Reduced number of 3H-nicotine and 3H-acetylcholine binding sites in the frontal cortex of Alzheimer brains
65. 11C] nicotine in the human brain: Difficulties in visulalizing specific receptor binding in vivo
66. Neuronal nicotinic receptors in the human brain
67. In vivo imaging of human cerebral acetylcholinesterase
68. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease
69. Chromosomal localization and physical linkage of the gene encoding the human a3,a5, and β4 neuronal nicotinic receptor subunits
70. Distribution of nicotinic receptors in human hippocampus and thalamus
71. Fascilitation of memory by post-trial administration of nicotine evidence for an attentional explanation
72. Nicotine and THA: Evidence for improved attention in patients with dementia of the Alzheimer type
73. The diversity of neuronal nicotinic acetylcholine receptors
74. The distribution of neuronal nicotinic acetylcholine receptors
75. Gene expression of the nicotinic acetylcholine receptor a4 subunit in the frontal cortex of Parkinson's disease patients
76. Nicotinic acetycholine receptors in Alzheimer's disease
77. Translation cell biology into therapeutic advances in Alzheimer's disease
78. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study
79. Synthesis and characterization of binding of 5[76Br]Bromo-3-[[2(S)-Azetidinyl]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain
80. 11C-labeled (S)-nicotine, (S)-3-methyl-5(1-methyl-2-pyrrolidinyl) isoxazole, and (R,S)-1-methyl-2-(3-pyridyl) azetidine as nicotinic receptor ligands for positron emission tomography studies
81. 11C]nicotine in rhesus monkeys
82. 3H]epibatidine in vitro autoradiography
83. 3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease
84. Development of ligands for in vivo imaging of cerebral nicotinic receptors
85. Oxidative posttranslational modification in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles
86. Molecular genetics of Alzheimer's disease
87. Tacrine and donepezil attenuate the neurotoxic effect of A beta (25-35) in rat PC12 cells
88. Expression of the a3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease
89. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly
90. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease
91. Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains
92. A comparision of FDG PET and IQNB SPECT in normal subjects and in patients with dementia
93. Cellular distribution of nicotinic acetylcholine receptor subunits mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization
94. Molecular cloning of a human neuronal nicotinic acetylcholine receptor β3-like subunit
95. Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety
96. Presynaptic nicotinic ACh receptors
97. Nicotine modulates the neurotoxic effect of beta-amyloid protein (25-35) in hippocampal cultures
98. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: Method development and differentiation of tracer delivery from receptor binding